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Background and aims: CCN family member 1 (CCN1) has recently been proposed as a novel biomarker of 
myocardial injury, improving prediction of 30-day and one-year mortality following acute coronary syndromes. 
Among ST-elevation myocardial infarction (STEMI) patients, we evaluated the utility of CCN1 measured 
immediately before primary percutaneous coronary intervention (PPCI) as a predictor of two earlier endpoints: 
final myocardial infarct size and post-infarction left ventricular ejection fraction (LVEF). Furthermore, we 
evaluated the impact of CCN1 on the discriminatory power of the CADILLAC score. 
Methods: STEMI patients were obtained from the SPUM-ACS cohort. Serum CCN1 was measured prior to PPCI. 
Linear regression assessed the association between CCN1, peak creatinine kinase (CK), and post-infarction LVEF. 
Cox models assessed an association between CCN1 and 30-day all-cause mortality. 
Results: CCN1 was measured in 989 patients with a median value of 706.2 ng/l (IQR 434.3–1319.6). A significant 
correlation between CCN1, myocardial infarct size (peak CK) and LVEF was observed in univariate and multi-
variate analysis (both p < 0.001). Even among patients with normal classical cardiac biomarker levels at the time 
of PPCI, CCN1 correlated significantly with final infarct size. CCN1 significantly improved prediction of 30-day 
all-cause mortality by the CADILLAC score (C-index 0.864, likelihood-ratio chi-square test statistic 6.331, p =
0.012; IDI 0.026, p= 0.050). 
Conclusions: Compared with classical cardiac biomarkers, CCN1 is potentially the earliest predictor of final 
myocardial infarct size and post-infarction LVEF. CCN1 improved the discriminatory capacity of the CADILLAC 
score suggesting a potential role in the very-early risk stratification of STEMI patients.   
1. Introduction 
CCN family member 1 (CCN1), also known as cysteine-rich angio-
genic inducer 61 (Cyr61), is a cysteine-rich extracellular matrix protein 
secreted by endothelial cells, fibroblasts, smooth muscle cells and car-
diomyocytes [1,2]. Its expression in cardiomyocytes is mediated by a 
host of stimuli including growth factors, angiotensin II, ischemia and 
tissue injury [3–5]. 
Amongst its numerous proposed functions, mounting evidence sug-
gests an important role of CCN1 in vascular and myocardial injury. In 
the context of atherosclerosis, human atherosclerotic coronary and ca-
rotid arteries demonstrate an increased expression of CCN1 within the 
vessel connective tissue [4]. Furthermore, we have recently identified 
CCN1 as an early biomarker of myocardial injury enabling improved risk 
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stratification among acute coronary syndrome patients [2]. Interest-
ingly, soluble CCN1 was shown to be rapidly released following coro-
nary artery occlusion, and even detectable prior to troponin, suggesting 
a role in the very initial stages of myocardial injury [2]. 
There is significant interest in the development of scoring systems 
that permit early risk stratification of patients following acute myocar-
dial infarction (MI) [6,7]. Based on information only available at the 
time of PPCI, the CADILLAC score was shown to identify ST-segment 
elevation myocardial infarction (STEMI) patients at high risk of both 
short- and long-term mortality [6]. Furthermore, early risk stratification 
has been shown to permit the early identification of patients at low risk 
of complications who may benefit from early discharge [8]. Myocardial 
infarct size is a known predictor of poor short- and long-term outcomes 
following MI [9–13]. In the acute context, large infarctions have been 
shown to be associated with the development of cardiogenic shock, 
acute heart failure and ventricular arrhythmias [14–17]. In theory, the 
early detection of large infarctions could provide complementary in-
formation to currently available scoring systems, thus facilitating the 
early identification of patients at high risk of complications and opti-
mising peri-PPCI care. 
Given the early release of CCN1 following myocardial injury, we 
aimed to evaluate the utility of CCN1 as an early predictor of final 
myocardial infarct size as compared to other classical biomarkers in 
patients presenting with STEMI. Furthermore, we evaluated the poten-
tial improvement of risk stratification by the CADILLAC risk score with 
the addition of pre-PPCI CCN1. 
2. Patients and methods 
2.1. Patients 
Data were obtained from the SPUM-ACS (Special Program University 
Medicine - Acute Coronary Syndromes) cohort of prospectively recruited 
patients admitted with ACS to four university hospitals in Switzerland. 
Further details of the SPUM-ACS cohort have been reported previously 
[18,19]. For the present study, the subgroup of patients hospitalised 
with STEMI between December 2009 and December 2012 who had 
blood drawn from the arterial sheath at coronary angiography prior to 
PPCI was selected (biomarker cohort). Blood was collected in serum 
tubes centrifuged, aliquoted, and stored at − 80 ◦C. 
2.2. Biomarker measurement and analysis 
All biomarkers were measured in blood samples taken from the 
arterial sheath at the time of PPCI. Additionally, peak CK levels were 
measured 12–24 h later (highest recorded value before decline). As re-
ported previously [2], concentrations of CCN1 were measured in du-
plicates of single serum aliquots blinded to the patient’s data by means 
of numbered ID codes using a semi-automated solid phase 
enzyme-linked immunosorbent assay (EIA-5108, DRG Instruments 
GmbH, Marburg, Germany). Due to the absence of defined upper limit of 
normal of CCN1, the upper interquartile value reported in healthy 
controls was used for analyses where an upper limit of normal was 
required (56.2 ng/l) [20]. Troponin T was measured in serum aliquots 
using a high-sensitivity assay (hsTnT) using electrochemiluminescence 
immunoassays analysed on a cobas e 602 reader (all Roche Diagnostics, 
Mannheim, Germany) with assay characteristics as reported by the 
manufacturer. Due to the presence of missing values, 129 patients were 
excluded from analyses stratifying by baseline CK values, 248 patients 
were excluded from analyses stratifying by baseline CK-MB values, and 
109 patients were excluded from analyses stratifying by baseline hsTnT 
values. 
2.3. Myocardial infarct size 
Myocardial infarct size was estimated using peak CK level as a 
surrogate marker. Due to the use of three different CK assays in this 
multicentre study, standardisation of CK values for comparison was 
achieved through use of the upper limit of normal of each assay. For the 
LVEF analysis, patients with previous MI were excluded from the anal-
ysis. LVEF was evaluated by ventriculography or by transthoracic 
echocardiography. 
2.4. 30-day all-cause mortality 
The incidence of events during follow-up was ascertained by tele-
phone consultation 30 days post discharge [19]. When patients could 
not be reached for follow-up, medical information was obtained from 
primary care physicians, family members, hospital records or a registry 
office. 
2.5. CADILLAC score 
The CADILLAC score was calculated as previously reported [6]. 
Briefly, age >65 years [2 points], Killip class ≥2 [3 points], baseline left 
ventricular ejection fraction <40% [4 points], anemia [2 points], renal 
insufficiency [3 points], triple-vessel disease [2 points], and 
post-procedural Thrombolysis In Myocardial Infarction flow grade [2 
points]). 
2.6. Statistical analysis 
Normally distributed, continuous variables are expressed as mean ±
SD and compared using the 2-tailed Student t-test. Non-normally 
distributed continuous variables are expressed as a median with inter-
quartile range and analysed using the Mann-Whitney U test. Compari-
sons between categorical variables were performed using the Pearson χ2 
test. Univariate and multivariate linear regression was used to identify 
the association between CCN1 prior to PPCI as a continuous variable 
and: (i) symptom-to-catheter time, (ii) peak CK, and (iii) LVEF. To 
facilitate the graphical representation of comparisons between CCN1 
and peak CK/LVEF, CCN1 values were divided into tertiles. Univariate 
and multivariate Cox proportional hazards models were used to evaluate 
the association between CCN1 level prior to PPCI and the primary 
endpoint. An optimal cut-off point for CCN1 was calculated using the 
Youden index. The discriminatory ability of the CADILLAC score with 
the addition of CCN1 and hsTnT was assessed using Harrell’s concor-
dance statistic (C-index), the likelihood ratio (LR) chi-square test and the 
integrated discrimination improvement (IDI) index. A p-value <0.05 
was defined as statistically significant. Statistical analysis was per-
formed using R version 3.5.1. 
3. Results 
3.1. Study population 
Among 1029 patients admitted with a STEMI in the SPUM-ACS 
biomarker cohort, 40 (3.9%) patients were excluded from the analysis 
due to the absence of a peak CK value. The remaining 989 (96.1%) 
patients were included in the infarct size analysis. The derivation of the 
study population for each sub-analysis is shown in Supplementary Fig. 1. 
Comparison of the final study population with the non-biomarker 
SPUM-ACS STEMI cohort demonstrated only small differences in base-
line characteristics (Supplementary Table 1). 
3.2. Baseline clinical characteristics stratified by CCN1 level prior to PPCI 
The median value of CCN1 was 706.2 ng/l (IQR 434.3–1319.6). 
When divided into tertiles 1 (T1), 2 (T2), and 3 (T3), this corresponded 
to CCN1 values of 371.6 ng/l (IQR 295.7–434.23 ng/l), 706.34 ng/l 
(604.4–836.5 ng/l), and 1740.9 ng/l (1323.1–2677.6 ng/l), respectively 
(p<0.001). Compared with patients in T1, those in T2 and T3 were 
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significantly older (T1: 60.4 years, T2: 63.3 years, T3: 62.5 years, p=
0.012), more likely to be female (T1: 15.5%; T2: 19.7%; T3: 28.0%, 
p<0.001), less likely to smoke (T1: 43.5%; T2: 49.7%; T3: 39.5%, p=
0.018), had a lower mean BMI (T1: 27.54 kg/m2; T2: 26.84 kg/m2; T3: 
26.47 kg/m2, p= 0.007), and a lower median eGFR (T1: 93.61 ml/min; 
T2: 92.22 ml/min; T3: 86.36 ml/min, p<0.001) (Supplementary 
Table 2). Patients in T2 and T3 also exhibited higher-risk clinical fea-
tures at the time of presentation, namely, a higher mean GRACE score 
(T1: 136.77; T2: 144.89; T3: 152.75, p<0.001), a higher proportion of 
patients in Killip class 3/4 (T1: 1.2%; T2: 4.5%; T3: 11.2%, p<0.001), 
and a lower median LVEF at the time of admission (T1: 50.0% (IQR 
45.0%–60.0%); T2: 50.0% (IQR 42.0%–59.8%); T3: 45.5% (IQR 40.0%– 
55.0%, p<0.001). 
3.3. Correlation between CCN1 and symptom-to-catheter time 
There was a significant negative correlation between symptom-to- 
catheter time and CCN1, with patients with the shortest symptom-to- 
catheter time having the highest CCN1 values prior to PPCI (T1: 4.42 
h (IQR 2.69, 9.62), T2: 3.73 h (IQR 2.45, 6.98), T3: 3.13 h (2.13, 5.25), 
p<0.001) (Supplementary Table 2). This correlation was confirmed 
with both univariate and multivariate linear regression controlling for 
age, sex, hypertension, diabetes, hypercholesterolemia, smoking, pre-
vious cardiovascular disease, GRACE score, Killip score, cardiac arrest at 
the time of presentation, and baseline eGFR (both p < 0.001). Stratifi-
cation of symptom-to-catheter times by quintile, demonstrated that 
CCN1 was highest among patients undergoing PPCI within 2 h of 
symptom onset (Fig. 1A). Conversely, both CK and hsTnT demonstrated 
a significant positive correlation with symptom-to-catheter time (Fig. 1B 
and C). 
3.4. Correlation between CCN1 and infarct size (peak CK and LVEF) 
CCN1 prior to PPCI stratified into tertiles exhibited a significant 
positive correlation with peak CK, a surrogate marker for infarct size 
(Fig. 2A). This correlation was confirmed with CCN1 as a continuous 
variable in both univariate and multivariate linear regression control-
ling for symptom-to-catheter time as well age, sex, hypertension, dia-
betes, hypercholesterolemia, smoking, previous cardiovascular disease, 
GRACE score, Killip score, cardiac arrest at the time of presentation, 
baseline eGFR, hsTnT, and NT-proBNP (both p < 0.001) (Supplementary 
Table 3). 
In a sub-analysis of 813 patients, after the exclusion of patients with a 
previous MI (n = 90) and those who did not undergo ventriculography 
(n = 86), CCN1 demonstrated a significant negative correlation with 
post-infarction LVEF as measured by ventriculography at the time of 
PPCI, with significantly reduced LVEF values with increasing CCN1 
tertile (Fig. 2B). This correlation was significant in both univariate and 
multivariate analysis (CCN1 as a continuous variable) controlling for 
symptom-to-catheter time as well age, sex, hypertension, diabetes, hy-
percholesterolemia, smoking, previous cardiovascular disease, GRACE 
score, Killip score, cardiac arrest at the time of presentation, baseline 
eGFR, hsTnT, and NT-proBNP (both p < 0.001) (Supplementary 
Table 4). 
In a subgroup of patients without previous MI, LVEF as measured by 
transthoracic echocardiography (TTE) was available (n = 274). The 
median time from PPCI to TTE was 2 days (IQR 1–3 days). CCN1 
demonstrated a negative correlation with post-infarction LVEF as 
measured by TTE with a significant difference between T1 and T3 
(Supplementary Fig. 2). This correlation was significant in both uni-
variate and multivariate analysis (covariates as per Supplementary 
Fig. 4). 
3.5. Correlation between CCN1 and infarct size after stratification by 
classical cardiac biomarker levels at the time of admission 
Among 341 patients with normal CK values prior to PPCI, CCN1 
tertile exhibited a significant positive correlation with peak CK values, a 
surrogate marker for infarct size (Fig. 3A). Among 187 patients with 
normal CK-MB values prior to PPCI, CCN1 tertile also exhibited a sig-
nificant positive correlation with peak CK values (Fig. 3B). Among 42 
patients with normal hsTnT levels prior to PPCI, there was a positive 
correlation between peak CK and CCN1 tertile with a significant dif-
ference found between CCN1 T3 with T1 (Fig. 3C). 
3.6. CCN1 versus hsTnT in the early detection of myocardial injury 
Of note, hsTnT also exhibited a significant positive correlation with 
both peak CK (Supplementary Table 3) and post-infarction LVEF (Sup-
plementary Table 4) in multivariate analysis. Due to the absence of a 
defined upper limit of normal for CCN1, the upper quartile value of 
CCN1 previously reported among healthy individuals was used as a 
surrogate cut off [20]. Only three patients had CCN1 values below this 
cut off (median 27.68 ng/l). 
An analysis of hsTnT tertiles exhibited a significant correlation with 
final infarct size (Supplementary Fig. 2A). However, among patients 
with normal CK values at the time of PPCI, hsTnT did not demonstrate a 
significant correlation with final infarct size (Supplementary Fig. 2B). 
3.7. CCN1 and 30-day all-cause mortality: addition of CCN1 to the 
CADILLAC score 
The all-cause mortality rate at 30 days was 2.4% (n = 24), with 58% 
(n = 14) of these deaths occurring in hospital. Univariate Cox regression 
Fig. 1. Correlation between symptom-to-catheter time by quintile and biomarker levels at the time of PPCI. 
(A) = CCN1; (B) = CK; (C) = hsTnT. p values derived using the Mann-Whitney U test. *p ≤ 0.05, **p ≤ 0.01, ***p ≤ 0.001, ****p ≤ 0.0001. 
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Fig. 2. Correlation between CCN1 prior to PPCI and (A) peak CK during the admission; (B) post-infarction LVEF as measured by ventriculography. 
p values derived using the Mann-Whitney U test. *p ≤ 0.05, **p ≤ 0.01, ***p ≤ 0.001, ****p ≤ 0.0001. 
Fig. 3. Correlation between CCN1 prior to PPCI and peak CK level, stratified by classical cardiac enzyme levels prior to PPCI. 
(A) Initial CK level; (B) initial CK-MB level; (C) initial hsTnT. Missing values: 129 patients excluded from analysis A due to missing baseline CK values; 248 patients 
excluded from analysis B due to missing baseline CK-MB values; 109 patients excluded from analysis C due to missing baseline hsTnT values. p values derived using 
the Mann-Whitney U test. *p ≤ 0.05, **p ≤ 0.01, ***p ≤ 0.001, ****p ≤ 0.0001. 
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demonstrated a significant association between CCN1 prior to PPCI and 
30-day all-cause mortality, with a hazard ratio of 1.040 (95% CI 
1.024–1.057, p<0.001) for every 100 ng/l increase in CCN1. This as-
sociation remained significant in multivariate analysis controlling for 
peak CK and post-infarction LVEF (HR 1.040, 95% 1.020–1.059, 
p<0.001). 
In univariate analysis, C-indices of CCN1 and the CADILLAC score 
were 0.676 (log-rank p<0.001) and 0.840 (log-rank p<0.001), 
respectively. Addition of CCN1 to the CADILLAC score resulted in an 
improvement in discriminatory performance (C-index 0.864, LR chi- 
square test statistic 6.331, p value 0.012; IDI 0.026, p value 0.050) 
(Fig. 4). The addition of hsTnT did not result in an improved discrimi-
natory performance (C-index 0.843, LR chi-square test statistic 2.600, p 
value 0.107; IDI 0.017, p value 0.189). The addition of both CCN1 and 
hsTnT significantly improved the model (C-index 0.864; LR chi-square 
test statistic 11.089, p value 0.004; IDI 0.056, p value 0.020). The 
addition of CCN1 to a model of CADILLAC + hsTnT significantly 
improved discriminatory performance (C-index 0.864; LR chi-square 
test statistic 8.490, p value 0.004; IDI 0.038, p value 0.020). Using the 
Youden index, an optimal cut-off point for CCN1 of 1852 ng/l was 
calculated for the prediction of 30-day all-cause mortality. Kaplan-Meier 
analysis confirmed significant increased mortality among STEMI patient 
with pre-PPCI CCN1 values above this threshold (Fig. 5). 
4. Discussion 
The principal findings of this study are:  
i. CCN1 measured immediately prior to PPCI exhibited significant 
correlations with peak CK, a surrogate marker of myocardial 
infarct size, and LVEF as measured by both ventriculography and 
TTE, with all correlations being independent of symptom-to- 
catheter time.  
ii. Even among patients with normal classical cardiac biomarkers 
(CK, CK-MB, hsTnT) at the time of PPCI, CCN1 measured imme-
diately prior to PPCI exhibited a significant positive correlation 
with final infarct size.  
iii. Addition of CCN1 to the CADILLAC score resulted in a small but 
significant improvement in its discriminatory power. 
4.1. CCN1 as an early marker of myocardial infarction 
Our results suggest a rapid increase of CCN1 following STEMI, with 
the highest values observed among patients undergoing testing within 2 
h of symptom onset. Even among patients with normal classical cardiac 
markers at the time of PPCI, CCN1 was already significantly elevated 
and correlated with final infarct size. Interestingly, this was the case 
among the 42 patients (4.3% of the cohort) with normal hsTnT at the 
time of PPCI, a biomarker known to be exquisitely sensitive to 
myocardial damage. 
In support of this finding is the rapid release of CCN1 seen in hy-
pertrophic cardiomyopathy patients undergoing trans-coronary ablation 
of septal hypertrophy [2]. Furthermore, in a mouse model of 
ischemia-reperfusion, ligation of the left anterior descending artery was 
associated with a rapid increase in CCN1 mRNA expression when 
compared with controls [2]. CCN1 expression has also been shown to be 
elevated in cardiomyocytes following myocardial infarction [5]. These 
results suggest that CCN1 plays a role in the very initial stages of 
myocardial injury. This rapid response appears to be mediated by the 
role of CCN1 as an immediate-early gene, thus permitting its expression 
to be induced rapidly and transiently in a protein-synthesis independent 
fashion [21]. This provides a plausible mechanism for the early peak in 
CCN1 levels following infarction and why raised levels can be detected 
before other cardiac markers are raised. 
CCN1 expression has been shown to be highly sensitive to a wide 
range of growth factors [22]. However, its expression is also sensitive to 
angiotensin II [4], hypoxia [23] and mechanical stretch [24], three 
factors that are theoretically perturbed in the early stages of myocardial 
infarction. Upon expression, the exact role of CCN1 is yet to be fully 
elucidated. However, CCN1 appears to exert numerous functions that 
may play a role in the pathophysiology of acute myocardial infarction. 
Fig. 4. Incremental discriminatory and reclassification capacities of CADILLAC 
score plus CCN1 and hsTnT. 
C-index = concordance statistic; LR = likelihood ratio; IDI = relative integrated 
discrimination improvement. 109 patients without hsTnT values on admission 
were excluded from this analysis thus n = 880. p values for each Cox model 
determined using the log rank test. p values associated with LR and IDI used to 
determine whether discriminatory performance was significantly improved. 
Fig. 5. Kaplan Meier survival analysis stratified by calculated CCN1 cut-off. 
An optimal CCN1 cut-off of 1852 ng/l was calculated using the Youden index. p 
value derived using the log rank test. 
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CCN1 has been implicated in acute inflammation, with expression 
increased by inflammatory cytokines such as IL-1 and TNFα [25]. CCN1 
has also been associated with fibroblast migration and monocyte 
adhesion [26,27], myocardial angiogenesis and remodelling of the 
vascular bed following myocardial injury [5]. 
Of note, only three patients (0.3% of the cohort) had normal CCN1 
values at the time of PPCI, as defined by the upper IQR reported in 
healthy controls [20]. Interestingly, these patients had a mean 
symptom-to-catheter time of over 10 h, and thus a possible explanation 
of low levels in these patients was that CCN1 had returned to normal 
following an earlier peak value. 
4.2. CCN1, prediction of infarct size, and risk stratification following 
STEMI patients 
The possible role of CCN1 in acute inflammation and its rapid release 
kinetics provide a possible explanation for its significant correlation 
with post-infarction LVEF and infarct size. Post-infarction LVEF is a well- 
established risk factor for mortality following MI, particularly due to 
ventricular arythmias [13,28], although it has limitations as an isolated 
risk stratifier since the majority of MI patients maintain a preserved or 
only moderately reduced LVEF [29]. However, myocardial infarct size 
has important implications for patient outcomes. Infarct size has been 
shown to be significantly associated with mortality and MACE following 
hospital discharge [9–12]. Infarct size following STEMI is also associ-
ated with adverse myocardial remodelling and heart failure following 
hospital discharge [30]. In the acute setting, myocardial infarct size has 
also been associated with early cardiogenic shock and acute heart failure 
[14]. Additionally, infarct size has been strongly correlated with the risk 
of ventricular arrhythmias during the index admission [15,16]. Terkel-
sen et al. demonstrated that ventricular arrythmias, supraventricular 
arrythmias and conduction abnormalities were frequently seen in the 90 
min following PPCI for STEMI. Furthermore, infarct size was shown to 
be significantly associated with sustained ventricular tachycardia and 
sinus bradycardia during this acute phase [17]. 
Given the importance of these acute complications of STEMI and 
their strong correlation with infarct size, the early prediction of large 
infarctions could provide significant benefits with regards to inpatient 
care. The early predictive power of CCN1 may provide an additional 
means of immediate risk stratification at the time of PPCI, enabling the 
optimisation of early inpatient surveillance and care immediately after 
PPCI. 
4.3. CCN1 improves the discriminatory capacity of the CADILLAC score 
Further support for the use of CCN1 in early risk stratification of 
STEMI patients is illustrated by its addition to the CADILLAC score, a 
score developed for the risk stratification of patients at the time of PPCI 
[6]. CCN1 has been shown to correlate significantly with all-cause 
mortality following myocardial infarction [2,31]. The present study 
demonstrates that the addition of CCN1 to the CADILLAC score results in 
a significant improvement in risk stratification. Despite hsTnT exhibit-
ing a significant correlation with infarct size and LVEF, it did not 
significantly improve the discriminatory power of the CADILLAC score. 
This suggests that CCN1 could provide added value to the very early risk 
stratification of STEMI patients, although we recognise that the 
improved discriminatory performance is modest. 
Interestingly, the present study demonstrates that this significant 
correlation between CCN1 and all-cause mortality is independent of 
infarct size (peak CK) and LVEF, suggesting that the association between 
CCN1 and MACE is more complex than simply that linked to myocardial 
infarct size. Further studies are needed to fully understand the roles of 
CCN1 following myocardial infarction. 
4.4. Limitations 
This analysis was based upon a single measurement of CCN1 at the 
time of PPCI. Inferences about the kinetics of CCN1 were made through 
comparisons of patients with differing symptom-to-catheter times. 
Although these inferences were corroborated by previously reported 
data [2], ideally patients would have had sequential CCN1 dosing at set 
intervals to fully define CCN1 release kinetics following STEMI. Addi-
tionally, CCN1 is not specific to the myocardium and thus it is possible 
that measured levels were not fully attributed to the myocardium. For 
example, CCN1 has been proposed as a potential ultra-early marker of 
acute kidney injury following renal ischemia [32]. However, given the 
context and the strong correlation with myocardial infarct size in this 
study, it is likely that the contribution of any non-cardiac source of CCN1 
was insignificant. A further limitation was the use of peak CK as a sur-
rogate marker of myocardial infarct size. Although this is a recognised 
method for estimating myocardial infarct size [33,34], an alternative 
method would have been through calculation of the area under the 
curve if numerous serum levels had been obtained at set intervals 
post-infarction. However, all biomarker-related predictors of myocar-
dial infarct size remain indirect and liable to be influenced by other 
factors such as the reperfusion intervention itself which can affect peak 
levels and enzyme release kinetics. The optimal infarct size estimation 
method would have been through the use of cardiac imaging such as 
cardiac MRI or nuclear medicine imaging. Additionally, although ven-
triculography is a recognised method for the evaluation of LVEF, it is 
performed at the time of PPCI and is less precise than TTE. A subgroup 
analysis confirmed the correlation between CCN1 and TTE-derived 
LVEF, but ideally all patients would have had TTE-derived LVEF avail-
able. Finally, this study only considered STEMI patients and thus further 
work is needed to demonstrate its efficacy in NSTEMI patients, and also 
in other acute cardiac conditions such as heart failure and myocarditis. 
4.5. Conclusion 
Among STEMI patients undergoing PPCI, CCN1 measured immedi-
ately before PPCI was an early predictor of both final myocardial infarct 
size and post-infarction LVEF, and improved the discriminatory capacity 
of the CADILLAC score. These findings suggest a role for CCN1 in the 
very early risk stratification and management of STEMI patients. 
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